<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096107</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00030099</org_study_id>
    <nct_id>NCT02096107</nct_id>
  </id_info>
  <brief_title>Novartis Everolimus Transition</brief_title>
  <official_title>Safety and Efficacy of Everolimus Transition in Minimizing Progressive Graft Dysfunction and Interstitial Fibrosis in Adult Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <brief_summary>
    <textblock>
      Transition from tacrolimus based triple therapy with Mycophenolate Mofetil (MMF) and steroids
      in stable renal transplant patients to low intensity tacrolimus, everolimus and prednisone
      will be associated with improvement in Glomular Filtration Rate (GFR) and allograft fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney Allograft Fibrosis Assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Measure and compare the change in interstitial fibrosis (morphometric analysis of trichrome stained slides) at one-year post-transplant in patients converted to everolimus, low intensity tacrolimus and prednisone versus the standard of care tacrolimus, mycophenolate and prednisone regimen.
The scale is a percentage of the tissue that demonstrates fibrosis. The scale range is 0 to 100%. The higher the percentage, the worse the fibrosis and the poorer the prognosis. A lower score (percentage) is therefore better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Function Measured by Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>1 year</time_frame>
    <description>Measure and compare the estimated GFR (using the 4-variable modified MDRD equation) in patients converted to everolimus, low intensity tacrolimus and prednisone versus the standard of care tacrolimus, mycophenolate and prednisone regimen, both at one year and two years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Allograft Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the patient and graft survival rates at one-year post-transplant in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing or Modifying Immunosuppressant Use</measure>
    <time_frame>2 year</time_frame>
    <description>Measure and compare the rates of immunosuppressant discontinuation and modification for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions</measure>
    <time_frame>2 year</time_frame>
    <description>Measure and compare the incidence of significant immunosuppressant-related adverse drug reactions for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>2 year</time_frame>
    <description>Compare the rates of post-transplant infections, including CMV, BK, and admissions to the hospital for infectious causes in each group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Graft Dysfunction</condition>
  <condition>Interstitial Fibrosis</condition>
  <arm_group>
    <arm_group_label>Low intensity Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low tacrolimus, everolimus, and steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tacrolimus, mycophenolate mofetil and steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
    <arm_group_label>Low intensity Tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Tacrolimus, mycophenolate mofetil and steroids</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age and able to give informed consent.

          2. Received a first or repeat cadaveric (including ECD) or living donor renal transplant.

          3. Patient has stable graft function, defined as no change of greater than 40% of
             baseline serum creatinine and no acute rejection during the past month.

          4. Currently receiving tacrolimus, mycophenolate mofetil and prednisone as their
             immunosuppression regimen

        Exclusion Criteria:

          1. Biopsy proven acute rejection episode that occurred within the past month.

          2. Malignancy within the past 3 years, except for non-melanoma skin cancer.

          3. Currently enrolled in an investigational drug trial.

          4. Woman of child bearing potential not utilizing an effective form of birth control.

          5. Patients with uncontrolled dyslipidemia, defined at serum fasting LDL &gt;200 mg/dL or
             serum fasting triglycerides &gt;500 mg/dL.

          6. Patients with a spot urine protein to creatinine ratio of &gt; 800 mg of protein per gram
             of creatinine.

          7. WBC &lt; 2,000 cells/mm3

          8. Platelets &lt; 75,000 cells/mm3

          9. Patients who have received an organ transplant other than a kidney.

         10. Patients with a history of biopsy proven FSGS, MPGN, or PGN.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Titte Srinivas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Taber</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina, Department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>July 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 8, 2018</results_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>Graft dysfunction</keyword>
  <keyword>Interstitial fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02096107/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Intensity Tacrolimus</title>
          <description>Low tacrolimus, everolimus, and steroids
Convert mycophenolate to everolimus (concentration goal of 3-8 ng/mL) with subsequent reduction in exposure to tacrolimus (concentration of 2-5 ng/mL)</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus (concentration goal of 5-12 ng/mL), mycophenolate mofetil and steroids</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Intensity Tacrolimus</title>
          <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="13.6"/>
                    <measurement group_id="B2" value="51.6" spread="12.1"/>
                    <measurement group_id="B3" value="51.3" spread="12.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.1" spread="17"/>
                    <measurement group_id="B2" value="84.7" spread="16.6"/>
                    <measurement group_id="B3" value="86.9" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="4.8"/>
                    <measurement group_id="B2" value="28.7" spread="4.5"/>
                    <measurement group_id="B3" value="28.7" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kidney Allograft Fibrosis Assessment</title>
        <description>Measure and compare the change in interstitial fibrosis (morphometric analysis of trichrome stained slides) at one-year post-transplant in patients converted to everolimus, low intensity tacrolimus and prednisone versus the standard of care tacrolimus, mycophenolate and prednisone regimen.
The scale is a percentage of the tissue that demonstrates fibrosis. The scale range is 0 to 100%. The higher the percentage, the worse the fibrosis and the poorer the prognosis. A lower score (percentage) is therefore better.</description>
        <time_frame>1 year</time_frame>
        <population>The number of subjects analyzed for the fibrosis assessment was 15 in each group, because biopsy samples for both baseline and end of follow-up were only able to be obtained from 15 subjects per group.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Intensity Tacrolimus</title>
            <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Allograft Fibrosis Assessment</title>
          <description>Measure and compare the change in interstitial fibrosis (morphometric analysis of trichrome stained slides) at one-year post-transplant in patients converted to everolimus, low intensity tacrolimus and prednisone versus the standard of care tacrolimus, mycophenolate and prednisone regimen.
The scale is a percentage of the tissue that demonstrates fibrosis. The scale range is 0 to 100%. The higher the percentage, the worse the fibrosis and the poorer the prognosis. A lower score (percentage) is therefore better.</description>
          <population>The number of subjects analyzed for the fibrosis assessment was 15 in each group, because biopsy samples for both baseline and end of follow-up were only able to be obtained from 15 subjects per group.</population>
          <units>% of fibrosis</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="17.9" upper_limit="25.7"/>
                    <measurement group_id="O2" value="20.8" lower_limit="18.4" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="18.6" upper_limit="28.1"/>
                    <measurement group_id="O2" value="27.8" lower_limit="18.7" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Measured by Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Measure and compare the estimated GFR (using the 4-variable modified MDRD equation) in patients converted to everolimus, low intensity tacrolimus and prednisone versus the standard of care tacrolimus, mycophenolate and prednisone regimen, both at one year and two years post-transplant.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Intensity Tacrolimus</title>
            <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Measured by Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Measure and compare the estimated GFR (using the 4-variable modified MDRD equation) in patients converted to everolimus, low intensity tacrolimus and prednisone versus the standard of care tacrolimus, mycophenolate and prednisone regimen, both at one year and two years post-transplant.</description>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" spread="14"/>
                    <measurement group_id="O2" value="56" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Allograft Survival</title>
        <description>Compare the patient and graft survival rates at one-year post-transplant in each group.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Intensity Tacrolimus</title>
            <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Allograft Survival</title>
          <description>Compare the patient and graft survival rates at one-year post-transplant in each group.</description>
          <units>percentage of patients graft survival</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing or Modifying Immunosuppressant Use</title>
        <description>Measure and compare the rates of immunosuppressant discontinuation and modification for each group.</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Intensity Tacrolimus</title>
            <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing or Modifying Immunosuppressant Use</title>
          <description>Measure and compare the rates of immunosuppressant discontinuation and modification for each group.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Drug Reactions</title>
        <description>Measure and compare the incidence of significant immunosuppressant-related adverse drug reactions for each group.</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Intensity Tacrolimus</title>
            <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Drug Reactions</title>
          <description>Measure and compare the incidence of significant immunosuppressant-related adverse drug reactions for each group.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection</title>
        <description>Compare the rates of post-transplant infections, including CMV, BK, and admissions to the hospital for infectious causes in each group.</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Intensity Tacrolimus</title>
            <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Infection</title>
          <description>Compare the rates of post-transplant infections, including CMV, BK, and admissions to the hospital for infectious causes in each group.</description>
          <units>percentage of subjects with infection</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Intensity Tacrolimus</title>
          <description>Low tacrolimus, everolimus, and steroids
Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Tacrolimus, mycophenolate mofetil and steroids
Standard of Care: Tacrolimus, mycophenolate mofetil and steroids</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Post-randomization hospitalization occurrence</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Immunosuppression held or modified</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Taber</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-3368</phone>
      <email>taberd@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

